Are Concord Biotech latest results good or bad?
Concord Biotech's latest results are positive, with net sales reaching Rs 429.88 crore and significant increases in profit before tax, profit after tax, and operating profit, marking the highest figures in five quarters. Overall, the company has demonstrated strong growth and improved operational efficiency.
Concord Biotech has reported notable financial results for the quarter ending March 2025, reflecting significant growth across various key metrics. The company's net sales reached Rs 429.88 crore, which represents a substantial increase compared to the average of the previous four quarters. This figure marks the highest net sales recorded by Concord Biotech in the last five quarters.Profit Before Tax (PBT), excluding other income, rose to Rs 174.16 crore, indicating a considerable increase over the previous four-quarter average. Profit After Tax (PAT) also saw a notable rise, climbing to Rs 140.39 crore, again surpassing the average from prior quarters.
The operating profit reached its highest level in five quarters at Rs 190.42 crore, with an operating profit margin of 44.30%, suggesting enhanced operational efficiency. Additionally, earnings per share (EPS) hit a five-quarter high at Rs 13.42, reflecting improved profitability.
The company experienced an adjustment in its evaluation, which may reflect the strong operational performance highlighted in these results. Overall, the data indicates that Concord Biotech has achieved significant growth in its financial metrics for the reported period.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
